— Regulator & Legal Basis
Regulator and Legal Basis
Medicines in Malaysia are regulated by the National Pharmaceutical Regulatory Agency (NPRA), an agency under the Ministry of Health (MOH). The NPRA carries out registration assessment, licensing and market surveillance, while the final approval decision is made by the Drug Control Authority (DCA).
01 · MINISTRY
Ministry of Health
Parent ministry
MOH
02 · REGULATOR
NPRA
National Pharmaceutical Regulatory Agency
Assesses, licenses, monitors
03 · FINAL APPROVAL
DCA
Drug Control Authority
Makes the approval decision
The main legal basis comprises the Sale of Drugs Act 1952, the Poisons Act 1952 and the Control of Drugs and Cosmetics Regulations 1984.
— Product Categories
Drug Categories and Classification
The NPRA regulates a broad range of products, principally:
01
Pharmaceutical Products
Western medicine
Including new chemical entities (NCEs), generics, biologics and vaccines; these must be formally registered and obtain a MAL registration number
02
Traditional Medicine
Traditional & herbal
Such as Chinese medicine, Malay traditional medicine and other herbal products
03
Health Supplement
Nutritional
Products intended mainly for nutritional supplementation
04
Cosmetics
Notification only
Under a notification regime since 2008, with a NOT number issued and no full safety and efficacy assessment; companies remain responsible for product safety compliance
One point deserves emphasis: medicines and medical devices fall under different regulatory systems. Medicines are regulated by the NPRA and carry registration numbers beginning with “MAL”, whereas medical devices are regulated by the Medical Device Authority (MDA) and classed from A to D by risk (see our separate guide on medical device registration).
Medicines themselves have no device-style “risk classification”. Instead, under the Poisons List of the Poisons Act, ingredients are placed in different control groups, which decide whether a medicine is sold on prescription, sold under pharmacist supervision, or may be sold openly:
01
Controlled prescription medicines
Sold on prescription only
02
Pharmacist-supervised medicines
Sold under pharmacist supervision
03
Freely available medicines
May be sold openly
— Licences Required
Types of Licence Required
Lawfully manufacturing, importing and selling medicines in Malaysia generally involves the following licences:
01
Manufacturer’s Licence
Local production
For companies manufacturing registered medicines in Malaysia; the applicant must be the Product Registration Holder (PRH) or a contract manufacturer, and the premises must meet Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP) standards
02
Import Licence
Bringing medicines in
For companies importing registered medicines into Malaysia; the applicant must be the PRH or an authorised importer, and storage facilities must meet GDP standards
03
Wholesaler’s Licence
Wholesale and distribution
For companies wholesaling or distributing registered medicines within Malaysia; GDP requirements likewise apply
In addition, a foreign manufacturer wishing to register a product in Malaysia must appoint a locally registered company as its Product Registration Holder (PRH). Malaysian regulations do not allow a foreign company to hold a product registration certificate directly; the PRH submits the application, holds the registration certificate, and bears the ongoing post-market surveillance and adverse-reaction reporting duties.
— Product Registration
Product Registration
Each medicine must be registered individually with the DCA and may be marketed only once a MAL registration number has been issued; the registration certificate is usually valid for 5 years. The application must be compiled in the ASEAN Common Technical Dossier (ACTD) format, covering modules such as administrative information, quality, and non-clinical and clinical data. Because Malaysia lies in a hot and humid climate zone (Climate Zone IVb), some products must also provide stability data that reflect local climatic conditions.
— Application Sequence
Application Sequence
Confirm the product category
Determine whether the product is a new drug, generic, biologic, traditional medicine or health supplement, which sets the applicable registration route
Appoint a Product Registration Holder (PRH)
A foreign manufacturer must first appoint a locally registered Malaysian company as its PRH
Apply for the relevant licences
The PRH and the relevant manufacturing, import or wholesale companies must first obtain a manufacturer’s, import or wholesaler’s licence (depending on role), and premises must meet GMP/GDP requirements
Prepare the registration dossier
Compile the complete technical dossier in ACTD format
Submit the registration application
Submit the application and pay the relevant fees
NPRA preliminary screening
A completeness check is generally completed within 15 working days; incomplete submissions are returned and do not enter the formal evaluation queue
Formal evaluation
The drug evaluation committee carries out a technical assessment, which generally takes about 210 working days for generics and about 245 working days for new chemical entities
Obtain the registration certificate and MAL number
Once approved, the DCA issues the registration certificate and MAL number, which must appear on the product label before marketing
Post-market obligations
After registration, the PRH must continue to meet adverse-reaction reporting duties and renew licences on schedule
In addition, from 2026 the NPRA is piloting an accelerated recognition pathway: for products already approved by the US FDA or the EU’s EMA, if the application is submitted within 3 months of the reference approval, evaluation time may be shortened to about 60 working days.
— How We Help
How We Can Help
Yingke Malaysia can help you understand the product classification and licence types required for medicine registration, prepare and compile the data and documents needed for registration, submit the QUEST3+ application on your behalf, and support you through the related compliance procedures, so the whole registration process runs smoothly.
※The above is compiled from the NPRA website and related public guidance and is a general summary only. Specific product classification, GMP/GDP requirements and evaluation timelines may change as official policy is updated; clients with an actual application in mind are advised to discuss their case with us, and to rely on the NPRA’s latest official guidance.